

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

CHANGE OF JOINT COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The board of directors (the “**Board**”) of China Pioneer Pharma Holdings Limited (the “**Company**”) announces that Ms. Yung Mei Yee (“**Ms. Yung**”) tendered her resignation (the “**Resignation**”) as the joint company secretary, authorised representative under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and authorised representative under the Companies Ordinance (Chapter 622 of Laws of Hong Kong) (collectively, the “**Joint Company Secretary and Authorised Representative**”) with effect from 29 March 2016. Ms. Yung confirmed that she has no disagreement with the Board and there are no circumstances related to her Resignation which need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company. The Company would like to thank Ms. Yung for her contributions to the Company in the past.

The Board is also pleased to announce that Ms. Mok Ming Wai (“**Ms. Mok**”) has been appointed in replacement of Ms. Yung as the Joint Company Secretary and Authorised Representative of the Company with effect from 29 March 2016.

Ms. Mok is a director of KCS Hong Kong Limited. She has over 20 years of professional and in-house experience in the company secretarial field. She is a fellow member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the United Kingdom.

The Company has applied to the Stock Exchange for, and obtained, an extension of the original waiver granted by the Stock Exchange at the time of listing of the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules during the period from 29 March 2016 to 4 November 2016 in relation to Mr. Min Le's ("Mr. Min") eligibility to act as the joint company secretary on the condition that:-

- (i) Mr. Min will be assisted by Ms. Mok during the waiver period;
- (ii) the Company is required to notify the Stock Exchange at the end of the waiver period for the Stock Exchange to re-visit the situation. It is expected that, after the end of the waiver period, the Company will be able to demonstrate that Mr. Min can satisfy Rules 3.28 and 8.17 of the Listing Rules after having the benefit of Ms. Mok's assistance such that a further waiver will not be necessary; and
- (iii) the Company will disclose details of the waiver, including reasons for the waiver and the waiver conditions, by way of an announcement.

The Board would like to welcome Ms. Mok to join the Company.

By Order of the Board
China Pioneer Pharma Holdings Limited
Li Xinzhou
Chairman

Hong Kong, 29 March 2016

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou, Mr. WANG Yiping and Mr. ZHU Mengjun as executive directors, Mr. WU Mijia as non-executive director and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive directors.